Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859207 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02859207 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 32 participants.
The verdict
NCT02859207, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.
Interventions
- DRUG E2609
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-01-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02859207
The ClinicalTrials.gov registry entry for NCT02859207 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E2609 is the first listed.
NCT02859207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02859207 about?
NCT02859207 is a clinical study titled "A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects". The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.
What is the current status of trial NCT02859207?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-08. Estimated completion is 2017-01-25.
What interventions are being tested in trial NCT02859207?
The interventions under investigation include: E2609 (DRUG).
Who is sponsoring clinical trial NCT02859207?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.